Llama antibodies could help fight SARS-CoV-2 variants
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
-
-
Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
-
HHS study showed 63-fold increase in Medicare Telehealthutilization during the Pandemic
On Dec. 3, 2021, a report from the U.S. Department of Health and Human Services (HHS) found that…
-
T2 Biosystems T2SARS-CoV-2 panel detected Omicron variant
On Dec. 1, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected the Omicron COVID-19 variant (B.1.1.529). The…
-
SIGA announced Health Canada regulatory approval of Oral TPOXX
On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 roller coaster
The COVID-19 Roller Coaster is a wild ride, strap yourself in and hold on… Cast of Characters: Senator…
-
Merck and Ridgeback Biotherapeutics provided update on results from MOVe-OUT study of Molnupiravir in adults with COVID-19
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
-
Pfizer provided U.S. Government with 10 million treatment courses of oral antiviral candidate to help combat COVID-19
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
-
Jubilant HollisterStier broke ground for $285 Million Spokane facility expansion
On Nov. 17, 2021, Jubilant HollisterStier broke ground for our $285 million Spokane facility expansion. This expansion is…
-
PNNL-led study delivered road map of lung development
On Nov. 17, 2021, Pacific Northwest National Laboratory (PNNL) announced researchers had compiled the most comprehensive road map…
-
Biotechnology | COVID-19 | FDA | Therapeutics | Vaccine
GSK and Vir Biotechnology announced U.S. government agreements to purchase sotrovimab, a COVID-19 treatment
On Nov. 17, 2021, GlaxoSmithKline and Vir Biotechnology announced U.S. government contracts totalling approximately $1 billion (USD) to…
-
Pfizer submitted Emergency Use Authorization for novel COVID-19 oral antiviral candidate
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
-
Illumina and Genetic Alliance Launch $120 million global initiative to increase equity and improve outcomes for families impacted by genetic disease
On Nov. 16, 2021, Illumina and Genetic Alliance announced the creation of the iHope Genetic Health program aimed…
-
Calgary reinstates fluoridation in City’s water System
On Nov. 14, 2021, the Calgary city council voted to reinstate fluoridation in Calgary’s waters. The count was…
-
Phase 3 analyses showed that a single dose of REGEN-COV provides long-term protection against COVID-19
On Nov. 8, 2021, Regeneron announced that the European Commission had approved the casirivimab and imdevimab antibody cocktail,…
-
Cocrystal Pharma’s SARS-CoV-2 protease inhibitors ddemonstrated pan-viral activity against human common Coronaviruses, Noroviruses, Rhinoviruses and Enteroviruses
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | USDA | Vaccine | Veterinary
The USDA confirmed COVID-19 in Hyenas at a Colorado Zoo
On Nov. 5, 2021, the USDA’s (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 in two spotted…
-
Pfizer’s COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
-
Ronapreve approved for additional indication as preventive treatment of symptomatic COVID-19 in Japan
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…
-
Oregon Health & Science University moved forward with hospital expansion
On Oct. 29, 2021, Oregon Health & Science University’s (OHSU) board of directors approved a project to expand…
-
Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
-
Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
-
Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
-
Quest Diagnostics provided K-12 School COVID-19 testing with Ginkgo Bioworks to support safer classrooms in Texas
On Oct. 20, 2021, Quest Diagnostics announced it had formed an agreement with the Texas Department of State…
-
NYU Langone Health’s Groundbreaking Transplant Offers Hope amid Organ Shortages
On Oct. 19, 2021, the first investigational transplant of a genetically engineered, nonhuman kidney to a human body…
-
Biotechnology | FDA | HIV | Therapeutics
U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations
On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…
-
Athenex and Center for Cell and Gene Therapy announced allowance of first U.S. patent around CAR-NKT cell therapy
On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine,…
-
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
On Oct. 15, 2021, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Tecentriq (atezolizumab)…
-
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
